Denali Therapeutics

DNLI Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$20.65

+4.93% today

52W: $10.57 – $23.77

52W Low: $10.57 Position: 76.4% 52W High: $23.77

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$3.3B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-45.69%

Return on Equity

Beta

1.1

Market sensitivity

Short Interest

9.97%

% of float sold short

Avg. Volume

1,815,160

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

14 analysts

Avg. Price Target

$36.14

+75.03% upside

Target Range

$25.00 – $42.00

About the Company

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's dis

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 503 Exchange: NMS